Dynamin 2, cell trafficking, and the triple-negative paradox
Dynamin 2, cell trafficking, and the triple-negative paradox |
|
https://doi.org/10.18632/oncotarget.26778
Sophia B. Chernikova,
John C. Game,
and J. Martin Brown
|
| 2336-2337 |
Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor
Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor |
|
https://doi.org/10.18632/oncotarget.26729
David L. Elion,
and Rebecca S. Cook
|
| 2338-2339 |
Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1’s elimination during colon cancer development and progression
Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1’s elimination during colon cancer development and progression |
|
https://doi.org/10.18632/oncotarget.26684
Badal Chandra Roy,
Ishfaq Ahmed,
Satish Ramalingam,
Venkatakrishna Jala,
Bodduluri Haribabu,
Prabhu Ramamoorthy,
John Ashcraft,
Joseph Valentino,
Shrikant Anant,
Venkatesh Sampath,
and Shahid Umar
|
| 2340-2354 |
Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors
Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors |
|
https://doi.org/10.18632/oncotarget.26760
Shirisha Jonnalagadda,
Sravan K. Jonnalagadda,
Conor T. Ronayne,
Grady L. Nelson,
Lucas N. Solano,
Jon Rumbley,
Jon Holy,
Venkatram R. Mereddy,
and Lester R. Drewes
|
| 2355-2368 |
Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma |
|
https://doi.org/10.18632/oncotarget.26792
Chuang Sun,
Aruna Mahendravada,
Brandon Ballard,
Brandon Kale,
Carlos Ramos,
John West,
Todd Maguire,
Katie McKay,
Eben Lichtman,
Sascha Tuchman,
Gianpietro Dotti,
and Barbara Savoldo
|
| 2369-2383 |
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay |
|
https://doi.org/10.18632/oncotarget.26797
Nike Beaubier,
Robert Tell,
Denise Lau,
Jerod R. Parsons,
Stephen Bush,
Jason Perera,
Shelly Sorrells,
Timothy Baker,
Alan Chang,
Jackson Michuda,
Catherine Iguartua,
Shelley MacNeil,
Kaanan Shah,
Philip Ellis,
Kimberly Yeatts,
Brett Mahon,
Timothy Taxter,
Martin Bontrager,
Aly Khan,
Robert Huether,
Eric Lefkofsky,
and Kevin P. White
|
| 2384-2396 |
The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations
The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations |
|
https://doi.org/10.18632/oncotarget.26800
Michiya Sugimori,
Yumiko Hayakawa,
Ryoi Tamura,
and Satoshi Kuroda
|
| 2397-2415 |
Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content
Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content |
|
https://doi.org/10.18632/oncotarget.26820
Tessa P. Sandberg,
Jan Oosting,
Gabi W. van Pelt,
Wilma E. Mesker,
Rob A.E.M. Tollenaar,
and Hans Morreau
|
| 2416-2416 |
